Zacks Investment Research on MSN
Can Novo Nordisk sustain its GLP-1 edge amid Lilly's growing pressure?
Novo Nordisk NVO is a dominant player in the GLP-1 space, marketing its semaglutide drugs under brand names Ozempic ...
The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday approved Novo Nordisk's (NVO) new single-dose 7.2mg semaglutide (Wegovy) by pen to treat adult patients with obesity, who have ...
Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients pay lower, "predictable" monthly prices. Eligible patients can ...
LONDON, March 31 (Reuters) - Novo Nordisk will launch a discounted subscription plan for U.S. Wegovy patients paying for the drug themselves, offering monthly prices up to nearly 30% below its ...
Prescription savings platform GoodRx is collaborating with pharma giant Novo Nordisk to make Ozempic and Wegovy pens available to eligible self-paying patients using GoodRx for $499 per month at ...
In recent years, though, certain drugmakers also have delivered a significant amount of growth. And this is thanks to one particular product portfolio: weight loss drugs. Novo Nordisk (NVO 2.31%) and ...
India is the first market where Novo Nordisk faces generic competition for semaglutide — the active ingredient in Ozempic and ...
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have been leaders in an area that's seen explosive demand over the past ...
JOHANNESBURG, Sept 3 (Reuters) - Aspen Pharmacare (APNJ.J), opens new tab, a sales agent for Eli Lilly, obtained regulatory approval to start launching the easy-to-use injector pen of the blockbuster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results